The sodium phenylbutyrate market has witnessed significant growth over the past few years owing to its wide range of applications in the treatment of urea cycle disorders. Sodium phenylbutyrate is an alternative pathway therapy medication used to treat people with urea cycle disorders which help to eliminate waste from the body. It assists in removing toxic levels of ammonia from the blood. Sodium phenylbutyrate works by binding with nitrogen in the body and allowing it to be excreted from the body through urine. The increasing prevalence of urea cycle disorders globally and growing awareness about its therapeutic role in managing disease symptoms are driving the demand for sodium phenylbutyrate. The Global sodium phenylbutyrate market is estimated to be valued at US$ 2.22 Bn in 2024 and is expected to exhibit a CAGR of 18% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the sodium phenylbutyrate market are Halliburton Co., Hifi Engineering Inc., Silixa Ltd., Schlumberger Limited, Banweaver, Omnisens SA, Future Fibre Technologies Ltd., Baker Hughes, Inc., Qintiq Group PLC, and Fotech Solutions Ltd. The major key players are focused on adopting inorganic growth strategies such as collaborations and partnerships to expand their market presence. The rising prevalence of urea cycle disorders is a major factor fueling the demand for sodium phenylbutyrate globally. With advancements in medical technology, early diagnosis of urea cycle disorders has become possible which is further facilitating the growth of the market. Manufacturers are investing heavily in research & development activities to develop more effective drug delivery systems and techniques for sodium phenylbutyrate which is supporting the market growth.
Market Trends
The Sodium Phenylbutyrate Market Size is witnessing a notable trend of shifting preference towards alternative drug delivery methods owing to advantages over traditional methods. Oral administering of sodium phenylbutyrate has certain limitations such as variable absorption which can negatively impact treatment outcomes. To address this, manufacturers are focusing on developing intravenous and transdermal drug delivery techniques. Another key trend gaining traction in the market is the increasing adoption of combination therapy approach using sodium phenylbutyrate with other ammonia scavenging drugs to enhance treatment efficacy. This is expected to open new avenues for market players over the forecast period.
Market Opportunities
Development of organic acid precursors: Manufacturers have opportunities to develop phenylbutyrate precursors that can be metabolized to phenylbutyrate acid in the body tissues. This can help enhance drug efficacy.
Emerging economies: Growing healthcare infrastructure and rising healthcare spending in developing Asian and Latin American countries presents significant opportunities for sodium phenylbutyrate manufacturers for geographic expansion.
The sodium phenylbutyrate market is anticipated to experience steady growth owing to increasing incidence of urea cycle disorders and continuous product innovations.
Impact of COVID-19 on Sodium Phenylbutyrate Market growth
The COVID-19 pandemic had a significant impact on the growth of the sodium phenylbutyrate market in the initial phases. The imposition of nationwide lockdowns and social distancing norms led to restrictions on non-essential medical care and pharmaceutical manufacturing. This disrupted supply chains and caused shortages of raw materials. Production was halted as facilities operated at reduced capacities due to safety protocols. Demand also declined from hospitals and healthcare centers catering to non-critical patients. However, in the post-COVID scenario, growth is projected to accelerate. Production levels are returning to normal and backlogged orders are being fulfilled. Stockpiles are being replenished to avoid future shortages. Telehealth and home delivery models for chronic conditions are supporting continued treatment access. Manufacturers are focusing on innovations to boost efficiencies and capacities to handle future healthcare needs.
The United States accounts for the major market share in terms of value. This is attributed to the large target patient pool suffering from urea cycle disorders in the country. Favorable reimbursement policies increase treatment affordability. Europe follows in terms of value concentration, led by markets like Germany, France and the UK. However, Asia Pacific is poised to emerge as the fastest growing regional market over the forecast period. This can be attributed to improving access to healthcare, rising healthcare expenditures, growing awareness regarding rare diseases and increasing disposable incomes in developing nations such as India and China. Initiatives by governments and NGOs to boost diagnostic rates of associated conditions also support market expansion.
Get more insights on Sodium Phenylbutyrate Market
Also read related article on Spinal Cord Injury Therapeutics Market
